CORRESPONDENCE of these had subsequent HTx, and one is still awaiting HTx after being placed on a LV assist device. Forty-two patients were followed for a mean 38±28 months (range, 3 months to 11 years). Following surgical PAB, intensive care stay was 12±7 (ventilation time 2±2 days); in-hospital stay was 38±25 days. Thus far, the majority (n= 34) has experienced functional recovery. None has required relisting for HTx. LV end-diastolic diameter decreased from 46±6 mm (z score 7±2) to 37±8 mm (z score 4±2) at discharge and 35±6 mm (z score 1±2) at the last follow-up. The corresponding LV ejection fraction increased from pre-PAB of 20±8%(n= 34) to 44±12% after 3 to 6 months (n= 34) and 60±10%(n= 34). The functional class improved from a median of IV (III–IV) to I (I–II). Median brain-type natriuretic peptide values obtained before PAB, after 3 to 6 months, and at the last follow-up (n= 20) decreased from 3046 pg/mL (interquartile range, 990–4911 pg/mL) to 183 pg/mL (interquartile range, 75–250 pg/mL) and 29.5 pg/mL (interquartile range, 18.5–46.5 pg/mL), respectively. At the end of the observation period, 34 of these patients recovered. Eight of the 42 patients showed improvement, but not yet full recovery, because their mean LV end-diastolic diameter measured 43±7 mm (12.5% z score decrease) and LV ejection fraction measured 25±10%(+ 39% increase). Considering overall death and transplant rate, 27 of the recovered patients (n= 34) had percutaneous pulmonary debanding after 14±9 months without relapse. The pressure gradient increased across the PAB form 41±14 at discharge to 70±22 mm Hg before debanding. PAB-world-network reports a new indication for an established surgical procedure along with encouraging short-to medium-term outcomes in a pediatric population with end-stage LV-DCM. Technically, PAB is simple, safe, effective, and affordable. It is a promising treatment strategy, especially in countries where transplant is not a realistic option. Introduction of PAB to the therapeutic arsenal represents a paradigm change in managing pediatric end-stage LV-DCM.